Qiagen, LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$5.1M
Doctors Paid
1,662
Transactions
3,282
2024 Total
$1.0M
Payment Breakdown by Category
Consulting$1.8M (34.7%)
Research$1.6M (30.5%)
Food & Beverage$65,813 (1.3%)
Royalty/License$62,938 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.8M | 511 | 34.7% |
| Unspecified | $1.6M | 60 | 30.5% |
| Space rental or facility fees (teaching hospital only) | $725,311 | 38 | 14.2% |
| Debt forgiveness | $514,597 | 536 | 10.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $349,868 | 19 | 6.8% |
| Food and Beverage | $65,813 | 2,054 | 1.3% |
| Royalty or License | $62,938 | 31 | 1.2% |
| Education | $26,834 | 16 | 0.5% |
| Honoraria | $22,732 | 13 | 0.4% |
| Gift | $7,573 | 2 | 0.1% |
| Long term medical supply or device loan | $1,747 | 1 | 0.0% |
| Grant | $650.00 | 1 | 0.0% |
Payments by Type
General
$3.6M
3,222 transactions
Research
$1.6M
60 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| NEUMODX 4PLEX V2 | $223,074 | 0 | 6 |
| Evaluation of 4th Generation QuantiFERON TB Test | $135,752 | 0 | 1 |
| Correlation between resistance gene signatures detected by the novel QIAstat-Dx BCID GN Plus AMR panel and phenotypic susceptibility against beta-lactam and non-beta-lactam antimicrobials | $100,000 | 0 | 1 |
| MULTI-CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX SARS-COV-2 ASSAY ON THE NEUMODX MOLECULAR SYSTEMS | $90,183 | 0 | 2 |
| MULTI CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX FLU A B RSV SARS COV 2 VANTAGE ASSAY ONTHE NEUMODX MOLECULAR SYSTEMS | $88,381 | 0 | 4 |
| EVALUATION OF QIAGEN BKV ASRS ON THE NEUMODX MOLECULAR SYSTEM | $85,105 | 0 | 4 |
| MULTI-CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX SARS-COV-2 ASSAY ON THE NEUMODX | $68,845 | 0 | 2 |
| Multi-Center Clinical Performance Evaluation of the NeuMoDx Flu-FluB-RSV-SARS CoV-2 Assay on the NeuMoDx Molecular Systems | $58,956 | 0 | 1 |
| EVALUATE NEUMODX EBV QUANT ASSAY | $56,956 | 0 | 1 |
| MULTICENTER STUDY, USING PROSPECTIVELY COLLECTED AND RESIDUAL NASOPHARYNGEAL SWAB SPECIMENS COLLECTED FROM SYMPTOMATIC INDIVIDUALS TO EVALUATE THE CLINICAL PERFORMANCE OF THE NEUMODX FLU A-B/RSV/SARS-COV-2 VANTAGE ASSAY ON THE NEUMODX SYSTEMS | $56,451 | 0 | 1 |
| COMPARISON OF QIASTAT-DX RESPIRATORY PANEL ASSAY WITH OTHER MULTIPLEX ASSAYS FOR DETECTION OF VIRAL PATHOGENS | $46,718 | 0 | 2 |
| MULTI-CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX FLUA/FLUB/RSV/SARS-COV-2 ASSAY ON THE NEUMODX MOLECULAR SYSTEMS | $43,949 | 0 | 1 |
| AN OBSERVATIONAL, MULTI-CENTER, PROSPECTIVE AND RETROSPECTIVE CLINICAL STUDY TO EVALUATE THE PERFORMANCE OF THE NEUMODX EBV QUANT ASSAY V2.0 ON THE NEUMODX MOLECULAR SYSTEMS IN IMMUNOCOMPROMISED TRANSPLANT PATIENTS | $26,660 | 0 | 1 |
| QIASTAT-DX CUTI PLUS AMR PANEL CLINICAL PERFORMANCE | $26,009 | 0 | 1 |
| A CLINICAL STUDY TO EVALUATE NEUMODX EBV QUANT ASSAY | $22,165 | 0 | 2 |
| MULTI-CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX FLUA-FLUB-RSV-SEVERE ACUTE RESPIRATORY SYNDROME-COV-2 ASSAY ON THE NEUMODX MOLECULAR SYSTEMS | $15,200 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 5
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Bruce Terrin, Md, MD | Pediatrics | Hackensack, NJ | $160.95 | $0 |
| Dr. Joseph Fruchter, Md, MD | Pediatrics | Hackensack, NJ | $160.94 | $0 |
| Dr. Beverly Ogden, M.d, M.D | Anatomic Pathology & Clinical Pathology | Baton Rouge, LA | $158.61 | $0 |
| Becky Campbell, Md, MD | Internal Medicine | Warner Robins, GA | $153.33 | $0 |
| Dr. David Fayngersh, M. D, M. D | Pediatrics | West New York, NJ | $152.34 | $0 |
| Rita Knause, Md, MD | Obstetrics & Gynecology | Tenafly, NJ | $152.34 | $0 |
| Helen Nunez, Md, MD | Pediatrics | Springfield, NJ | $152.34 | $0 |
| Dr. James Perez | Internal Medicine | Elizabeth, NJ | $151.03 | $0 |
| Winston Umali, Md, MD | Pediatrics | Jersey City, NJ | $145.84 | $0 |
| Ramdas Kumar, M.d, M.D | Nephrology | Thousand Oaks, CA | $145.18 | $0 |
| Evelyn Ventura, Md, MD | Pediatrics | Passaic, NJ | $143.96 | $0 |
| Sarah Kunin, M.d, M.D | Internal Medicine | Birmingham, AL | $143.22 | $0 |
| Dr. Michael Luther, M.d, M.D | Family Medicine | Marion, AL | $143.21 | $0 |
| Dr. Delia Rappaport, Md, MD | Pediatrics | Hackensack, NJ | $143.02 | $0 |
| Dr. Ramon Sandoval, Md, MD | Internal Medicine | Paterson, NJ | $141.60 | $0 |
| Elma Castillo, M.d, M.D | Adolescent Medicine | West New York, NJ | $141.03 | $0 |
| Dean Grace, Do, DO | Occupational Medicine | Ionia, MI | $140.33 | $0 |
| Dr. Thomas Keaveney, M.d, M.D | General Practice | Lansing, MI | $140.33 | $0 |
| Vincent Codella, Do, DO | Family Medicine | Union, NJ | $134.65 | $0 |
| Dr. Juan Desueza, M.d, M.D | Internal Medicine | Paterson, NJ | $133.63 | $0 |
| Dr. Meera Ravikumar, Md, MD | Internal Medicine | Chicago, IL | $133.14 | $0 |
| Dr. Ricardo Ferraz, Md, MD | Adolescent Medicine | Sarasota, FL | $133.02 | $0 |
| Dr. David Sidebottom, M.d, M.D | Infectious Disease | Lowell, MA | $130.80 | $0 |
| Dr. Adam Weston, M.d, M.D | Infectious Disease | Lowell, MA | $130.80 | $0 |
| Sara Nasiek, M.d, M.D | Pediatrics | Wayne, NJ | $128.61 | $0 |
Ad
Top Products
- MDx Quantiferon $135,752
- QUANTIFERON $50,406
Associated Products (8)
- QUANTIFERON $50,406
- QUNATIFERON-SARS-COV-2 $33,750
- QIAREACH SARS-COV-2 ANTIGEN TEST $24,769
- NEUMODX EBV QUANT ASSAY $19,760
- MDX QUANTIFERON $19,383
- QIAstat-Dx Respiratory Panel $16,667
- QIAREACH ANTI-SARS-COV-2 TOTAL TEST $15,660
- QUANTIFERON-TB GOLD PLUS $12,427
Payment Categories
- Food & Beverage $65,813
- Consulting $1.8M
- Research $1.6M
- Royalties $62,938
About Qiagen, LLC
Qiagen, LLC has made $5.1M in payments to 1,662 healthcare providers, recorded across 3,282 transactions in the CMS Open Payments database. In 2024, the company paid $1.0M. The top product by payment volume is MDx Quantiferon ($135,752).
Payments were distributed across 98 medical specialties. The top specialty by payment amount is Internal Medicine ($1.1M to 254 doctors).
Payment categories include: Food & Beverage ($65,813), Consulting ($1.8M), Research ($1.6M), Royalties ($62,938).
Qiagen, LLC is associated with 8 products in the CMS Open Payments database, including QUANTIFERON, QUNATIFERON-SARS-COV-2, and QIAREACH SARS-COV-2 ANTIGEN TEST.